Cadrenal Therapeutics Reports Stockholder Votes; Increases Equity Plan

What Happened

• Cadrenal Therapeutics, Inc. filed an 8-K on Sept. 29, 2026 reporting results from its Sept. 24, 2026 annual stockholder meeting.
• Stockholders approved Amendment No. 2 to the 2022 Successor Equity Incentive Plan to increase available shares for awards by 323,542, bringing the total to 1,000,000 shares. The proxy describing the amendment was filed Aug. 3, 2026 and the full amendment is filed as Exhibit 10.1 to the 8-K.
• At the meeting (record date July 27, 2026; 3,567,592 shares outstanding), Quang X. Pham was elected as a Class I director (term through the 2029 annual meeting) and WithumSmith+Brown, P.C. was ratified as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• Annual meeting date: Sept. 24, 2026; record date: July 27, 2026. Quorum: 2,155,341 shares present.
• Equity plan increase: +323,542 shares, new plan ceiling = 1,000,000 shares.
• Director election (Class I): Quang X. Pham — For: 1,039,666; Withheld: 14,342; Broker non‑votes: 1,101,333.
• Auditor ratification: WithumSmith+Brown, P.C. — For: 2,110,693; Against: 39,121; Abstentions: 5,527.

Why It Matters

• The approved increase to the equity incentive plan expands shares available for employee and director awards, which can help support hiring and retention but also increases potential share dilution.
• Re-election of a director and ratification of the auditor provide continuity in corporate governance and the company’s audit relationship for 2026.
• These are governance-level actions (not operating results); investors should note the dilution impact from the plan amendment when assessing share count and potential future equity compensation.